Beam Therapeutics Deal History & Licensing Activity
Beam Therapeutics is a biotech headquartered in US. Over the past three years, Beam Therapeutics has been involved in 3 licensing and acquisition transactions, with a primary focus on mRNA (1 deal). The company currently has 8 active clinical trials, primarily in Oncology.
Deals (12mo)
1
Active Trials
8
Top Modality
mRNA
Focus Area
Oncology
Beam Therapeutics Pipeline Focus
Therapeutic areas and modalities where Beam Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Beam Therapeutics Strategic Signals
Key indicators of Beam Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Beam Therapeutics Clinical Pipeline
Beam Therapeutics has 8 active clinical trials across 2 development phases.
2
Unknown
6
Phase 1
See How Your Asset Matches Beam Therapeutics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
mRNA Benchmarks
Upfront, milestone, and royalty benchmarks for mrna deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Beam Therapeutics Licensing & Deal Activity
Beam Therapeutics is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Beam Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Beam Therapeutics include Oncology (3 deals and trials), Rare Disease (3 deals and trials), and Hematological Malignancies (1 deal and trial). In terms of modality, Beam Therapeutics has shown particular interest in mrna, gene therapy, car-t.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Beam Therapeutics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Beam Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.